About: dbpedia:Pertuzumab   Goto Sponge  NotDistinct  Permalink

An Entity of Type : owl:Thing, within Data Space : platform.yourdatastories.eu:8890 associated with source document(s)

Pertuzumab (also called 2C4, trade name Perjeta) is a monoclonal antibody marketed by Genentech for the treatment of HER2-positive breast cancer, in combination with trastuzumab and docetaxel. The first of its class in a line of agents called "HER dimerization inhibitors". By binding to HER2, it inhibits the dimerization of HER2 with other HER receptors, which is hypothesized to result in slowed tumor growth.

AttributesValues
rdfs:comment
  • Pertuzumab (also called 2C4, trade name Perjeta) is a monoclonal antibody marketed by Genentech for the treatment of HER2-positive breast cancer, in combination with trastuzumab and docetaxel. The first of its class in a line of agents called "HER dimerization inhibitors". By binding to HER2, it inhibits the dimerization of HER2 with other HER receptors, which is hypothesized to result in slowed tumor growth.
foaf:depiction
  • External Image
ATC prefix
  • L01
ATC suffix
  • XC13
CAS number
  • 380610-27-5
FDA UNII code
  • K16AIQ8CTM
thumbnail
is product of
Faceted Search & Find service v1.13.91 as of Nov 14 2017


Alternative Linked Data Documents: ODE     Content Formats:       RDF       ODATA       Microdata      About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data]
OpenLink Virtuoso version 07.20.3212 as of Mar 29 2016, on Linux (x86_64-unknown-linux-gnu), Single-Server Edition (68 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2026 OpenLink Software